hVIVO plc (LON:HVO – Get Free Report)’s stock price fell 6.8% during trading on Thursday . The company traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). 2,518,262 shares were traded during trading, a decline of 26% from the average session volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.25).
hVIVO Stock Down 6.8 %
The company has a market cap of £129.95 million, a P/E ratio of 636.67 and a beta of 0.97. The company’s 50-day moving average is GBX 23.58 and its two-hundred day moving average is GBX 26.77. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.
About hVIVO
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
- Five stocks we like better than hVIVO
- Dividend Capture Strategy: What You Need to Know
- 3 Legacy Tech Companies Reemerging as AI Leaders
- What Are Dividend Challengers?
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Expert Stock Trading Psychology Tips
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
